Inhye E Ahn

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Topics

Randomized Controlled Trial

Chronic Lymphocytic Leukemia

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

The New England journal of medicine

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Inhye E Ahn, Danielle M Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A Walker, Robert Black, Josie Montegaard, Alvaro J Alencar, Leyla Shune, Mohammad Omaira, Caron A Jacobson, Philippe Armand, Samuel Y Ng, Jennifer Crombie, David C Fisher, Ann Steward LaCasce, Jon Arnason, Ephraim P Hochberg, Ronald W Takvorian, Jeremy S Abramson, Jennifer R Brown, Matthew S Davids
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood advances 8 (4) (2024)
Inhye E Ahn, Danielle M Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A Walker, Robert Black, Josie Montegaard, Alvaro J Alencar, Leyla Shune, Mohammad Omaira, Caron A Jacobson, Philippe Armand, Samuel Y Ng, Jennifer Crombie, David C Fisher, Ann Steward LaCasce, Jon Arnason, Ephraim P Hochberg, Ronald W Takvorian, Jeremy S Abramson, Jennifer R Brown, Matthew S Davids
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood advances 8 (4) (2024)
Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, Chingiz Underbayev, Pamela L Tuma, Xin Tian, Lita A Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, Chingiz Underbayev, Pamela L Tuma, Xin Tian, Lita A Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner
CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jennifer A Woyach, Paolo Ghia, John C Byrd, Inhye E Ahn, Carol Moreno, Susan M O'Brien, Daniel M Jones, Leo W K Cheung, Elizabeth Chong, Kevin Kwei, James P Dean, Danelle F James, Adrian Wiestner
B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Maria Joao Baptista, Sivasubramanian Baskar, Erika M Gaglione, Keyvan Keyvanfar, Inhye E Ahn, Adrian Wiestner, Clare Sun
Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (16) (2021)
Arthur L Shaffer, James D Phelan, James Q Wang, DaWei Huang, George W Wright, Monica Kasbekar, Jaewoo Choi, Ryan M Young, Daniel E Webster, Yandan Yang, Hong Zhao, Xin Yu, Weihong Xu, Sandrine Roulland, Michele Ceribelli, Xiaohu Zhang, Kelli M Wilson, Lu Chen, Crystal McKnight, Carleen Klumpp-Thomas, Craig J Thomas, Björn Häupl, Thomas Oellerich, Zachary Rae, Michael C Kelly, Inhye E Ahn, Clare Sun, Erika M Gaglione, Wyndham H Wilson, Adrian Wiestner, Louis M Staudt
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. Blood cancer discovery 2 (6) (2021)
Sanjal H Desai, Clifton Mo, Erika M Gaglione, Constance M Yuan, Maryalice Stetler-Stevenson, Xin Tian, Irina Maric, Laura Wake, Mohammed Z Farooqui, Dennis C Drinkwater, Susan Soto, Janet Valdez, Thomas E Hughes, Pia Nierman, Jennifer Lotter, Gerald E Marti, Christopher Pleyer, Clare Sun, Jeanine Superata, Cydney Nichols, Sarah E M Herman, Margaret A Lindorfer, Ronald P Taylor, Adrian Wiestner, Inhye E Ahn
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. Leukemia & lymphoma 62 (8) (2021)
Christian Brieghel, Kathrine Aarup, Mathias Husted Torp, Michael Asger Andersen, Christina W Yde, Xin Tian, Adrian Wiestner, Inhye E Ahn, Carsten Utoft Niemann
Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (16) (2021)
Inhye E Ahn, Xin Tian, Adrian Wiestner
Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations. The New England journal of medicine 383 (5) (2020)
Inhye E Ahn, Xin Tian, David Ipe, Mei Cheng, Maher Albitar, L Claire Tsao, Lei Zhang, Wanlong Ma, Sarah E M Herman, Erika M Gaglione, Susan Soto, James P Dean, Adrian Wiestner
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (6) (2020)
Erika Tissino, Dania Benedetti, Sarah E M Herman, Elisa Ten Hacken, Inhye E Ahn, Kari G Rabe, Francesca Maria Rossi, Michele Dal Bo, Pietro Bulian, Riccardo Bomben, Elisabeth Bayer, Andrea Härzschel, Julia Christine Gutjahr, Massimiliano Postorino, Enrico Santinelli, Ayed O Ayed, Francesco Zaja, Annalisa Chiarenza, Gabriele Pozzato, Alexandre Chigaev, Larry A Sklar, Jan A Burger, Alessandra Ferrajoli, Tait D Shanafelt, Adrian Wiestner, Giovanni Del Poeta, Tanja Nicole Hartmann, Valter Gattei, Antonella Zucchetto
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. The Journal of experimental medicine 215 (2) (2018)